Page 1,111«..1020..1,1101,1111,1121,113..1,1201,130..»

Renowned neurodegeneration expert receives top accolade – News – The University of Sydney

Posted: March 16, 2020 at 6:47 am

Internationally renowned neurodegeneration academic, Professor Glenda Halliday, who is shaping the treatment of non-Alzheimers dementias and Parkinsons disease, has been recognised as one of Australias leading female medical researchers.

Professor Halliday, from the Faculty of Medicine and Health and the Brain and Mind Centre, was awarded the NHMRC Elizabeth Blackburn Investigator Grant Award for Leadership in Clinical Medicine and Science.

The award is named in honour of Professor Elizabeth Blackburn, an Australian molecular biologist who received the Nobel Prize in Physiology or Medicine in 2009.

Professor Hallidays groundbreaking research has shaped current international diagnostic criteria and recommendations for neurodegenerative patient identification and management.

After developing quantitative methods to evaluate the symptoms of patients with Parkinson's disease, she revealed more extensive neurodegeneration in Parkinson's and related syndromes than previously thought.

Her 70 strong research team in the Brain and Mind Centres Dementia and Movement Disorders Lab is now focused on finding biomarkers that identify under-recognised non-Alzheimer diseases to target with disease modifying strategies.

Deputy Vice-Chancellor (Research) Professor Duncan Ivison congratulated Professor Halliday on this prestigious award, adding that her work is at the forefront of understanding the origins of neurodegeneration and developing new treatments.

Glenda has rightly been recognised as one of Australias, and the worlds, leading experts on neurodegeneration. Her research is critical to improving the lives of those with Parkinsons, dementia and other neurodegenerative diseases and we are proud to support her and her team to conduct this important research.

Professor Halliday has produced more than 430 publications, has a h-index of 83, and was named among the world's most influential academics on the Clarivate Analytics 2019 Highly Cited Researchers List.

She is on the editorial boards of five international journals, and on the scientific advisory boards for a number of international organisations and research institutes. She is a Fellow of the Australian Academy of Health and Medical Sciences.

The University of Sydney is ranked 18th in the world for medicine, according to the latest QS Subject rankings.

See more here:
Renowned neurodegeneration expert receives top accolade - News - The University of Sydney

Posted in Molecular Medicine | Comments Off on Renowned neurodegeneration expert receives top accolade – News – The University of Sydney

Aging eyes and the immune system – Science Magazine

Posted: March 16, 2020 at 6:47 am

A central promise of regenerative medicine is the ability to repair aged or diseased organs using stem cells (SCs). This approach will likely become an effective strategy for organ rejuvenation, holding the potential to increase human health by delaying age-related diseases (1). The successful translation of this scientific knowledge into clinical practice will require a better understanding of the basic mechanisms of aging, along with an integrated view of the process of tissue repair (1).

The advent of SC therapies, now progressing into clinical trials, has made clear the many challenges limiting the application of SCs to treat disease. Our duty, as scientists, is to anticipate such limitations and propose solutions to effectively deliver on the promise of regenerative medicine.

Degenerating tissues have difficulty engaging a regulated repair response that can support efficient cell engraftment and restoration of tissue function (2). This problem, which I encountered when trying to apply SC-based interventions to treat retinal disease, will likely be an important roadblock to the clinical application of regenerative medicine approaches in elderly patients, those most likely to benefit from such interventions. I therefore hypothesized that the inflammatory environment present in aged and diseased tissues would be a major roadblock for efficient repair and that finding immune modulators with the ability to resolve chronic inflammation and promote a prorepair environment would be an efficient approach to improve the success of SC-based therapies (2, 3).

Immune cells, as sources and targets of inflammatory signals, emerged naturally as an ideal target for intervention. I chose to focus on macrophages, which are immune cells of myeloid origin that exist in virtually every tissue of the human body and which are able to reversibly polarize into specific phenotypes, a property that is essential to coordinate tissue repair (3, 4).

If there is an integral immune modulatory component to the process of tissue repair that has evolved to support the healing of damaged tissues, then it should be possible to find strategies to harness this endogenous mechanism and improve regenerative therapies. Anchored in the idea that tissue damage responses are evolutionarily conserved (5), I started my research on this topic using the fruit fly Drosophila as a discovery system.

The fruit fly is equipped with an innate immune system, which is an important player in the process of tissue repair. Using a well-established model of tissue damage, I sought to determine which genes in immune cells are responsible for their prorepair activity. MANF (mesencephalic astrocyte-derived neurotrophic factor), a poorly characterized protein initially identified as a neurotrophic factor, emerged as a potential candidate (6). A series of genetic manipulations involving the silencing and overexpression of MANF and known interacting partners led me to the surprising discovery that, instead of behaving as a neurotrophic factor, MANF was operating as an autocrine immune modulator and that this activity was essential for its prorepair effects (2). Using a model of acute retinal damage in mice and in vitro models, I went on to show that this was an evolutionarily conserved mechanism and that MANF function could be harnessed to limit retinal damage elicited by multiple triggers, highlighting its potential for clinical application in the treatment of retinal disease (2).

Having discovered a new immune modulator that sustained endogenous tissue repair, I set out to test my initial hypothesis that this factor might be used to improve the success of SC-based therapies applied to a degenerating retina. Indeed, the low integration efficiency of replacement photoreceptors transplanted into congenitally blind mice could be fully restored to match the efficiency obtained in nondiseased mice by supplying MANF as a co-adjuvant with the transplants (2). This intervention improved restoration of visual function in treated mice, supporting the utility of this approach in the clinic (7).

Next, my colleagues and I decided to address the question of whether the immune modulatory mechanism described above was relevant for aging biology and whether we could harness its potential to extend health span. We found that MANF levels are systemically decreased in aged flies, mice, and humans. Genetic manipulation of MANF expression in flies and mice revealed that MANF is necessary to limit age-related inflammation and maintain tissue homeostasis in young organisms. Using heterochronic parabiosis, an experimental paradigm that involves the surgical joining of the circulatory systems of young and old mice, we established that MANF is one of the circulatory factors responsible for the rejuvenating effects of young blood. Finally, we showed that pharmacologic interventions involving systemic delivery of MANF protein to old mice are effective therapeutic approaches to reverse several hallmarks of tissue aging (8).

A confocal fluorescence microscope image of a giant macrophage shows MANF (mesencephalic astrocyte-derived neurotrophic factor) expression in red.

The biological process of aging is multifactorial, necessitating combined and integrated interventions that can simultaneously target several of the underlying problems (9). The potential of immune modulatory interventions as rejuvenating strategies is emerging and requires a deeper understanding of its underlying molecular and cellular mechanisms.

One expected outcome of reestablishing a regulated inflammatory response is the optimization of tissue repair capacity that naturally decreases during aging (3). Combining these interventions with SCbased therapeutics holds potential to deliver on the promise of regenerative medicine as a path to rejuvenation (1).

PHOTO: COURTESY OF J. NEVES

GRAND PRIZE WINNER

Joana Neves

Joana Neves received undergraduate degrees from NOVA University in Lisbon and a Ph.D. from the Pompeu Fabra University in Barcelona. After completing her postdoctoral fellowship at the Buck Institute for Research on Aging in California, Neves started her lab in the Instituto de Medicina Molecular (iMM) at the Faculty of Medicine, University of Lisbon in 2019. Her research uses fly and mouse models to understand the immune modulatory component of tissue repair and develop stem cellbased therapies for age-related disease.

PHOTO: COURTESY OF A. SHARMA

FINALIST

Arun Sharma

Arun Sharma received his undergraduate degree from Duke University and a Ph.D. from Stanford University. Having completed a postdoctoral fellowship at the Harvard Medical School, Sharma is now a senior research fellow jointly appointed at the Smidt Heart Institute and Board of Governors Regenerative Medicine Institute at the Cedars-Sinai Medical Center in Los Angeles. His research seeks to develop in vitro platforms for cardiovascular disease modeling and drug cardiotoxicity assessment. http://www.sciencemag.org/content/367/6483/1206.1

FINALIST

Adam C. Wilkinson

Adam C. Wilkinson received his undergraduate degree from the University of Oxford and a Ph.D. from the University of Cambridge. He is currently completing his postdoctoral fellowship at the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University, where he is studying normal and malignant hematopoietic stem cell biology with the aim of identifying new biological mechanisms underlying hematological diseases and improving the diagnosis and treatment of these disorders. http://www.sciencemag.org/content/367/6483/1206.2

View post:
Aging eyes and the immune system - Science Magazine

Posted in Molecular Medicine | Comments Off on Aging eyes and the immune system – Science Magazine

We Can Be Better Than COVID-19 – The Bulwark

Posted: March 16, 2020 at 6:47 am

Everyone is looking for silver-linings in the COVID-19 pandemic, which is only natural. In the tech sector, for example, many people have decided that one of the up-sides of the crisis is that it has demonstrated the fantastic power of artificial intelligence.

The argument is that AI helped doctors anticipate, diagnose, and formulate treatments for COVID-19.

The truth is somewhat less fantastic.

In MITs Technology Review, Will Douglas debunked these claims, concluding that AI could help with the next pandemicbut not with this one. Where AI has made an impact, its been in ways that we might not like. The Wall Street Journals Tech News podcast points out that the most consequential implementation of AI during this crisis may have been Chinas use of facial recognition to identify and report citizens who were using public transportation without wearing masks.

In other words, so far AI has been most useful as a means to extending an authoritarian regimes surveillance capabilities, and in this one instance that may have contributed some unmeasurable public health benefit. Yay?

And advances in the biotech sector have not been terribly impressive, either.

We are more than 60 years into the molecular age (Watson and Crick first published their double helix structure of DNA in 1953) and the two most valuable remediation techniques at our disposal are the admonitions to (1) wash your hands and (2) isolate the afflicted. According to the CDC, this latter technique was developed in the Middle Ages.

This isnt to say that weve learned nothing in the ensuing 700 years: the supportive care afforded to those who are critically ill is an extraordinary achievement, the result of iterativeand often unheraldedimprovements in processes over time. And it seems that real and rapid progress is being made toward the development of potential therapies (to treat the disease), and vaccines (to protect from it)but the proof here will be in the eventual clinical trials.

To their credit, physicians and other health care providers tend to be painfully aware of the limitations of their armamentarium, and feel a powerful sense of humility in response to this pandemic.

Yet the worst attitude elicited by the current crisis isnt hubris, but disdain. There is a sense emanating from certain sectors that there would be karmic justice if MAGA zealots who believe more strongly in the Deep State than in science were to become preferentially infected with coronavirus because they dismissed precautions around social distancing and regarded these public health admonitions as an anti-Trump conspiracy.

You may have heard of the Darwin Award, the satirical prize given to people who are killed by their own foolishness. Example: A lawyer who dies after running through a skyscraper window, trying to demonstrate its safety. Or a rhino poacher stomped to death by an elephant (then digested by a lion).

There is, here and there in the tech and science communities, the whispered belief that Trump supporters who disdain public health advice like social distancing are lining up to win their own Darwin Awards and that if they start dropping like flies, they will have gotten what they deserved.

This notion is deplorable and runs directly counter to the spirit of medicine. And it must be stamped out. Immediately.

One of the best things about being a doctor is the bedrock commitment to helping each person in need. When you approach a patient as a physician, you dont take on the complex moral calculus of how complicit someone may or may not be in their condition, and then titrate care and concern accordingly. You attend to each person equally, and without qualification.

Beyond that, to be a physician is to recognize that diseases afflict all of us; while those with the least are often the most susceptible to illness, all of us can, at a moments notice, move from the realm of the well to the realm of the sick. As Susan Sontag eloquently wrote,

Illness is the night-side of life, a more onerous citizenship. Everyone who is born holds dual citizenship, in the kingdom of the well and in the kingdom of the sick. Although we all prefer to use only the good passport, sooner or later each of us is obliged, at least for a spell, to identify ourselves as citizens of that other place.

As long as disease has existed, theres been a tendency to attribute illness to a failing of the sufferer; yet while someones behavior and choices often plays a role in illnesssmoking predisposes to lung cancer, and obesity contributes to the prevalence of type 2 diabetesdoctors know that although prevention is important, illness can strike anyone. Which is why physicians aspire to offer you understanding, rather than judgment.

When I started my medical training, one of the things which struck me is just how much so many people are dealing with, all the time. We get a sense of this from the occasional celebrity revelations: rapper Lil Wayne coping with epilepsy; Giants great Tiki Barber managing his sickle cell disease; Supreme Court Justice Sonia Sotomayor living with type 1 diabetes since she was a child; the revelation that President John F. Kennedy suffered from an adrenal gland deficiency called Addisons Disease; and former Colorado Governor John Hickenlooper, former Illinois Senator Carol Moseley Braun, and Colorados senior Senator Michael Bennet, who each have overcome dyslexia.

The arrival of a global pandemic upon our shores, despite the insistent skepticism of the president and his supporters, should not be looked at as a victory of science over the heathens.

Instead, this pandemic should remind us just how far science and technology still have to go, while reawakening our sense of responsibility to care for all the afflicted, to the best of our ability, and with all our hearts.

The most appropriate response to misplaced arrogance and self-regard isnt the transposition of these qualities from politicians to scientists.

Its to replace these reflexes with the humility that science demands, and the empathy our patientsall of themdeserve.

Continue reading here:
We Can Be Better Than COVID-19 - The Bulwark

Posted in Molecular Medicine | Comments Off on We Can Be Better Than COVID-19 – The Bulwark

Rapid response COVID-19 science conducted by father and daughter virologists – Medicine Hat News

Posted: March 16, 2020 at 6:47 am

By Michael Tutton, The Canadian Press on March 15, 2020.

HALIFAX For a Halifax father and daughter dedicated to taking on global infectious diseases, the novel coronavirus has led to their latest, exhausting push to create tests and vaccines to save lives.

Alyson Kelvin, 39, and David Kelvin, 65, are once again in the trenches of a race to find long-term solutions, hoping for success while public interest and funding remain in place.

Alyson, a virologist working at Dalhousie University, has been seconded to the Vaccine and Infectious Disease Organization International Vaccine Centre in Saskatoon since mid-February to test vaccines in lab animals.

Meanwhile, back in Halifax, her father a professor in Dalhousies department of microbiology and immunology is immersed in creating a portable test kit to identify the severity of the illness for people who test positive for the virus.

Both are engaged in rapid response science, which has meant fast-tracked federal funding is paired with swift collaboration with scientists around the globe working on the pandemic.

I work from waking up until going to sleep, the younger Kelvin said during an interview from Saskatoon. My whole life has shifted. My husband and children are back in Halifax.

The pursuit of infectious disease solutions is a family passion, she adds.

Thats how I was raised, she says, referring to her observation of her fathers work on HIV-AIDS as a young woman.

Her career has already included work on the first SARS outbreak, the Zika virus and various influenza outbreaks. Her father has worked on many of the same outbreaks.

David Kelvin has several projects on the go, including a push to identify biomarkers in this instance molecules that activate white blood cells that will indicate if a person who tests positive for the virus is at risk of developing a severe case of COVID-19.

The goal is to create a kit that would allow health care providers to determine in as little as 20 minutes who needs to be hospitalized, which could potentially keep vitally needed beds and respirators open for patients most in need.

Rather than going through a lengthy process of days, we can do it rapidly and provide assistance to doctors who are looking at a surge of patients and can decide who should receive hospitalization at the earlier stages of the disease, he explained in an interview.

In Saskatoon, his daughter, accompanied by a doctoral student and technician from Dalhousie, is working with coronavirus investigator Darryl Falzarano at the International Vaccine Centre to carry out animal tests for potential vaccines.

Her knowledge of ferrets is key as the animal was identified as a helpful model for human immune reactions in the SARS outbreak in 2002-03, and is believed to also be a useful lab animal for testing vaccines for the novel coronavirus.

Her team is working with three vaccines developed by Halifax molecular virologist Chris Richardson, also a Dalhousie University scientist, and a vaccine developed by a scientist at the centre.

While their work has to move as swiftly as possible, she says that doesnt mean compromising a meticulous methodology to avoid any safety risks. Without animal-testing stages in vaccine research, its possible errors can occur, she said.

Its especially important because the original SARS vaccines werent effective and sometimes led to more severe disease in the end. So, this is an important stage of the evaluation, she said.

Having vaccines a year from now for the novel coronavirus may still be vital, the researcher said.

We may see waves of it in the same way we do with influenza . Having a vaccine and being ready for this particular virus could help us if that becomes a reality, she said.

Richardson, who has worked in the field for four decades, said regular vaccine research can take several years.

Typically it could be two years and clinical trials can go even further, he said in an interview.

He says one of the frustrations is that funding can dry up after an outbreak prompts an initial surge in interest. The veteran virologist said he hopes it will be different this time.

The father and daughter both say they are relying on Ottawa to keep funding flowing in the months to come, even if the pandemic calms.

This call for the initial research was $1 million, David Kelvin said. Its a fantastic initial start. We realize and know that to continue this through the full duration of the infection cycle, were going to have to have a lot more investment.

Hes hopeful the biomarkers for the potential test kits will emerge from his collaborators in China and Italy in four to 10 weeks, but further work will then require commercial collaborators interested in producing the kits.

The family connections in the research are likely to continue. Alyson Kelvin said that as her fathers teams kits evolve, her team will be able to test their effectiveness.

We can experimentally induce viral infection and disease, and we can evaluate the kits using samples from our experiments before theyre used in people, she said.

Amid the current pressure for results, David Kelvin says it may be time for government to reflect on whether the funding for vaccine research should have been in place sooner and on a steadier basis.

Too often, he says, interest has faded when the worst of an international infection passes.

We need to impress on everyone this is our third pandemic in 20 years, he said. We dont want to respond in an emergency fashion every time. We want to be really well prepared.

This report by The Canadian Press was first published March 15, 2020.

You must be logged in to post a comment.

See the original post here:
Rapid response COVID-19 science conducted by father and daughter virologists - Medicine Hat News

Posted in Molecular Medicine | Comments Off on Rapid response COVID-19 science conducted by father and daughter virologists – Medicine Hat News

The way people live their lives can be mined, too – The Economist

Posted: March 16, 2020 at 6:47 am

Mar 12th 2020

THREADWORMS ARE trending, according to the app on Johannes Schildts phone. The app was created by Kry, the Swedish digital health-care firm Mr Schildt runs. It offers information on the sicknesses for which people are currently booking doctors appointments, as well as on things specifically important to its userit keeps Mr Schildt, who suffers from hay fever, up to date with the pollen count. It lets him book an appointment with a family doctor or a specialist, and indeed to have such an appointment by phone. None of this sounds particularly stretching. But in health care, it counts as radical.

According to the Organisation for Economic Co-operation and Development (OECD), a club of richer nations, the world creates 2.5 exabytes of data a daythousands of times what even the grandest sequencing centre can produce in a month. Of those which get stored, 30% pertain to health. The trove contains insights into the health of populations and of individuals, the efficacy of drugs and the efficiency of health-care systems, the failings of doctors and the financial health of insurers. But OECD countries typically spend less than 5% of their health budgets managing these data, much less than is the norm in other areas. By failing to make the most of their potential, these countries are wasting $600bn a yearroughly the GDP of Sweden.

This underutilised resource has attracted the attention of a panoply of private companies, from minnows like Kry to giants like Amazon, Apple, Facebook and Google. Governments, hospitals and insurers, they think, will pay for what they glean from it. So will individualswho will often pay for the privilege of supplying yet more data off their own bat. Mobile phones log their users physical activity, creating records used by many of the billions of health-related smartphone apps downloaded globally every year (1.7bn in 2013, 3.7bn in 2017). Make sense of all this data for them, the argument goes, and you can make money helping people stay healthy and warning them of disease.

As with the genome twenty years ago, some scepticism is warranted. But in time a picture of a life built up from the genomes underlying recipe, from medical histories and tests that profile specific bodily functions, and from the monitoring of every step and heartbeat, will allow personalised, preventive medicine to be rolled out across entire populations. All these layers define the medical essence of a human being, says Eric Topol, head of the Scripps Research Translational Institute in La Jolla, California.

Adding real-world data to genome-based profiles would undoubtedly be useful. Michael Joyner of the Mayo Clinic in Rochester, Minnesota, and Nigel Paneth at Michigan State University argue that characteristics such as family history, neighbourhood, socioeconomic circumstances, height and girth still outperform genetic profiling as predictors for all sorts of health outcomes. This does not mean genetic information is without value; it means it needs context.

Various new frontiers in diagnosis are being explored. Firms across the world are competing to develop liquid biopsies that can detect and characterise cancers by means of fragments of DNA in the blood; other molecular markers could reveal other diseases. But so could the digital footprints people leave when they decide whether to leave the house, what to buy, what to search for or what to stream.

Sometimes the footprints may be just that. Dan Vahdat, who runs Medopad, a health-technology firm in London, says conditions as varied as Parkinsons disease, depression and breast cancer can all have a distinctive effect on a patients gait. He speculates that with enough data covering different behaviours it will be possible to identify digital biomarkers capable of predicting the risk of Alzheimers or a heart attack. Work by Dr Topol has already shown that spikes in resting heart ratemore common when people have an infectionallow someone with access to lots of fitbits to see when flu is breaking out in the population.

The recognition of such patterns is clearly a job for the machine-learning techniques driving the current expansion of AI. These techniques are already being used to interpret diagnostic tests, sometimes with real success. An AI system for prostate cancer diagnosis developed by the Karolinska Institute in Stockholm has held its own against a panel of 23 international experts; a nine-country trial is now assessing how much it can reduce the workload of doctors. But recent research published in The Lancet Digital Health, a journal, suggests some caution is advisable. Looking at around 20,000 studies of medical AI systems that claimed to show that they could diagnose things as well as health-care professionals, it found that most had methodological flaws.

One particular worry with machine learning in general is that bias in the training sets from which the computers learn their stuff can mean that the algorithms do not work equally well for all members of the population. Medical research has a poor historical record on such matters, for example when it does not match clinical-trial populations to the population at large, or excludes women of child-bearing age from trials. Machine learning could bake in such biases, and make them invisible.

Excessive optimism that edges into barefaced hype is just one cause for concern about datomics. Privacy is, as always, an issue. The amount of data that parts of the NHS have shared with Google has worried some Britons. Conversely, some researchers feel hampered by constraints such as those of Europes General Data Protection Regulation, says Claire Gayrel of the EUs data protection authority. They see it as an obstacle to innovation. Ms Gayrel treats that with equanimity: I dont think it is a bad thing to think slower, especially in health.

As well as worries over what researchers or companies might do with personal data, there are reasonable concerns over how safe they can keep it. A cyberattack on Premera Blue Cross, an American insurer, may have exposed the medical data of 11m customers in 2015.

There is also the challenge of cost. Whatever claims are made early on and whatever benefits they may demonstrate, new technologies have a marked, persistent tendency to drive up spending on health in rich countries. There is no obvious reason to think that, just because sequencing, data processing and some forms of machine learning are getting cheaper, their ever greater application to health care will drive down costs.

One reason is that, although knowledge may be power, it may also be a needless worry. A DNA test that seems to tell you some of your future, or a watch that can pick up atrial fibrillation, may seem great to users; they are less enticing to health systems that have to deal with diagnoses which are not, in themselves, clinically relevant. Last year the New York Times reported that a period-tracking app which also evaluated womens risk of polycystic-ovary syndrome, a hormonal problem, was recommending that an improbably large number of its users see their doctors.

Trustable intermediariessuch as government health-care systems, regulators and reputable insurerswill help consumers to know what works best. They should also be able to help each other. Not everyone is motivated to improve their health, and even avid consumers of health data will rarely have the same sense of common cause as people with congenital diseases and their families. But health concerns bring people together, and through supporting each other they may develop new mechanisms for change.

Because health systems look to the needs of the many, personalised medicine will hit its stride only when it can show that its approaches work in the round. But as people get more used to customising their lives through online services that know what they want, health care will get pulled along. There will be many false correlations, privacy violations, and errors along the way. But in the end, people of all sorts will benefit from being understood as unique.

This article appeared in the Technology Quarterly section of the print edition under the headline "The coming of the datome"

See the original post here:
The way people live their lives can be mined, too - The Economist

Posted in Molecular Medicine | Comments Off on The way people live their lives can be mined, too – The Economist

Global Cell Therapy (Autologous, Allogeneic) Markets to 2027 – Yahoo Finance

Posted: March 15, 2020 at 2:47 pm

Dublin, March 10, 2020 (GLOBE NEWSWIRE) -- The "Cell Therapy Market Size, Share & Trends Analysis Report by Use-type (Research, Commercialized, Musculoskeletal Disorders), by Therapy Type (Autologous, Allogeneic), by Region, and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

The global cell therapy market size is expected to reach USD 8.8 billion by 2027 at a CAGR of 5.4%, over the forecast period.

Cellular therapies hold a great therapeutic promise across various clinical applications. This has resulted in substantial global investments in research and clinical translation. Moreover, rapid advances in stem cell research hold the potential to fulfill the unmet demand of pharmaceutical entities, biotech entities, and doctors in disease management. These factors have boosted revenue growth for the market.

Currently, there are a limited number of FDA-approved commercial stem and non-stem cell therapies in the market. Furthermore, LAVIV (Azficel-T), manufactured and commercialized by Fibrocell Technologies, witnessed revenue wind-down in the past years. Key developers are making substantial investments in the adoption of advanced technologies to address the aforementioned challenges.

The introduction of proprietary cell lines is recognized as the primary means by which a single cell can be exploited for the production of a robust portfolio of candidates. Companies are leveraging new technologies not only for the expansion of their product portfolio but also for establishing out-licensing or co-development agreements with other entities to support their product development programs.

For instance, MaxCyte has more than 40 high-value cellular therapy partnership programs within immune-oncology, regenerative medicine, and gene editing, including fifteen clinical-stage programs. Increase in the number of collaborations between entities for product commercialization is anticipated to accelerate market revenue to a major extent in the coming years.

In Asia-Pacific, the market is anticipated to witness significant growth over the forecast period. This is attributed to rising awareness cellular therapies among patients and healthcare entities in chronic disease management. In addition, availability of therapeutic treatment at lower prices is also driving the regional market. Japan is likely to witness fast growth over the forecast period attributed to increasing research activities on regenerative medicine.

Further key findings from the report suggest:

Key Topics Covered

Chapter 1 Executive Summary

Chapter 2 Research Methodology

Chapter 3 Cell Therapy Market Variables, Trends & Scope3.1 Market Segmentation & Scope3.1.1 Market driver analysis3.1.1.1 Rise in number of clinical studies pertaining to the development of cellular therapies3.1.1.2 Rising adoption of regenerative medicine3.1.1.3 Introduction of novel platforms and technologies3.1.2 Market restraint analysis3.1.2.1 Ethical concerns related to stem cell research3.1.2.2 Clinical issues pertaining to development & implementation of cell therapy3.1.2.2.1 Manufacturing issues3.1.2.2.2 Genetic instability3.1.2.2.3 Stem cell culture condition3.1.2.2.4 Stem cell distribution after transplant3.1.2.2.5 Immunological rejection3.1.2.2.6 Challenges associated with allogeneic mode of transplantation3.2 Penetration & Growth Prospect Mapping For Therapy Type, 20193.3 Cell Therapy Market (Stem & Non-stem Cells)-Swot Analysis, by Factor (Political & Legal, Economic and Technological)3.4 Industry Analysis - Porter's3.5 Cell Therapy Market (Stem & Non-stem Cells)-Regulatory Landscape

Chapter 4 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Use-type Estimates & Trend Analysis4.1 Cell Therapy Market (Stem & Non-stem Cells): Use-type Movement Analysis4.2 Clinical-use4.3 Research-use

Chapter 5 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Therapy Type Estimates & Trend Analysis5.1 Cell Therapy Market (Stem & Non-stem Cells): Therapy Type Movement Analysis5.2 Allogeneic Therapies5.3 Autologous Therapies

Chapter 6 Cell Therapy Market (Stem & Non-stem Cells) Categorization: Regional Estimates & Trend Analysis, by Product6.1 Cell Therapy Market (Stem & Non-stem Cells) Share by Regional, 2019 & 20276.2 North America6.3 Europe6.4 Asia-Pacific6.5 Latin America6.6 MEA

Chapter 7 Competitive Landscape7.1 Strategy Framework7.2 Company Profiles7.2.1 Kolon TissueGene, Inc.7.2.2 JCR Pharmaceuticals Co. Ltd.7.2.3 MEDIPOST7.2.4 Osiris Therapeutics, Inc.7.2.5 Stemedica Cell Technologies, Inc.7.2.6 Cells for Cells7.2.7 NuVasive, Inc.7.2.8 Fibrocell Science, Inc.7.2.9 Vericel Corporation7.2.10 Pharmicell Co. Ltd.7.2.11 Anterogen Co. Ltd.7.2.12 Celgene Corporation

For more information about this report visit https://www.researchandmarkets.com/r/5bjbpt

Story continues

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See original here:
Global Cell Therapy (Autologous, Allogeneic) Markets to 2027 - Yahoo Finance

Posted in Cell Therapy | Comments Off on Global Cell Therapy (Autologous, Allogeneic) Markets to 2027 – Yahoo Finance

Second patient cured of HIV using stem cell therapy – European Pharmaceutical Review

Posted: March 15, 2020 at 2:47 pm

Researchers report that a patient who underwent stem-cell transplantation and a chemotherapy drug regimen has been cured of HIV.

An HIV patient to undergo stem cell transplantation from donors with a HIV-resistant gene no longer suffers from the condition, according to a new study. Researchers reveal that there was no active viral infection in the patients blood 30 months after they stopped anti-retroviral therapy, making him the second person cured of HIV.

However, they report that although there was no active viral infection in the patients body, remnants of integrated HIV-1 DNA remained in tissue samples, which were also found in the first patient to be cured of HIV. The authors suggest that these can be regarded as so-called fossils, as they are unlikely to be capable of reproducing the virus.

We propose that these results represent the second ever case of a patient to be cured of HIV. Our findings show that the success of stem cell transplantation as a cure for HIV, first reported nine years ago in the Berlin patient, can be replicated, said lead author on the study, Professor Ravindra Kumar Gupta at the University of Cambridge, UK.

The London and Berlin patient are examples of using the CCR5 gene in curative therapies outside of gene editing

He emphasised that as a high-risk treatment, this therapy is unlikely to be offered widely to patients with HIV who are on successful antiretroviral treatment.

In 2011, a patient based in Berlin (the Berlin patient) was the first HIV patient to be reportedly cured of the virus three and half years after undergoing similar treatment. This therapy included total body irradiation, two rounds of stem cell transplant from a donor who carried a CCR532/32 gene, which is resistant to HIV and finally a chemotherapy drug regimen. The transplant aimed to make the virus unable to replicate in the patients body, whilst the body irradiation and chemotherapy targeted any residual HIV virus.

The patient reported in this study (the London patient), underwent one stem-cell transplantation and a reduced-intensity chemotherapy drug regimen, without whole body irradiation. In 2019, it was reported that his HIV was in remission and the new study provides follow-up viral load blood test results at 30-months, as well as a modelling analysis to predict the chances of viral re-emergence.

Ultrasensitive viral load sampling from the London patients cerebrospinal fluid, intestinal tissue or lymphoid tissue was taken at 29 months after interruption of antiretroviral therapy (ART) and viral load sampling of his blood at 30 months. At 29 months, CD4 cell count (indicators of immune system health and stem cell transplantation success) was measured and analysed to identify the extent to which the patients immune cells have been replaced by those derived from the transplant.

The results showed no active viral infection was detected in samples of the patients blood at 30 months or in his cerebrospinal fluid, semen, intestinal tissue and lymphoid tissue 29 months after stopping ART.The patient also had a healthy CD4 cell count, suggesting he recovered well from the transplant, with his CD4 cells replaced by cells derived from the HIV-resistant transplanted stem cells. Furthermore, 99 percent of his immune cells were derived from the donors stem cells, indicating the stem-cell transplant had been successful.

The authors highlight that their case study of the London patient represents a step towards a less intensive treatment approach. They suggest that the long-term remission of HIV can be achieved using reduced intensity drug regimens, with one stem cell transplant (rather than two) and without total body irradiation.

However, being only the second reported patient to undergo this experimental treatment successfully, the authors note that that the London patient will need continued, but much less frequent, monitoring for re-emergence of the virus.

Speculating on what their results might mean for future developments of HIV cures that utilise the CCR5 gene, co-author on the study, Dr Dimitra Peppa at the University of Oxford, UK, said: Gene editing using the CCR5 has received a lot of attention recently. The London and Berlin patient are examples of using the CCR5 gene in curative therapies outside of gene editing. There are still many ethical and technical barriers eg, gene editing, efficiency and robust safety data to overcome before any approach using CCR5 gene editing can be considered as a scalable cure strategy for HIV.

The study was published in The Lancet HIV.

HIV

Here is the original post:
Second patient cured of HIV using stem cell therapy - European Pharmaceutical Review

Posted in Cell Therapy | Comments Off on Second patient cured of HIV using stem cell therapy – European Pharmaceutical Review

Cancer Stem Cell Therapy Market Global Size, Demand-sales, Suppliers by Key Applications 2019 Detailed Analysis and Growth Aspects on Manufacturing…

Posted: March 15, 2020 at 2:47 pm

In this report, the global Cancer Stem Cell Therapy market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Cancer Stem Cell Therapy market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Cancer Stem Cell Therapy market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2542097&source=atm

The major players profiled in this Cancer Stem Cell Therapy market report include:

The following manufacturers are covered:AVIVA BioSciencesAdnaGenAdvanced Cell DiagnosticsSilicon Biosystems

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeAutologous Stem Cell TransplantsAllogeneic Stem Cell TransplantsSyngeneic Stem Cell TransplantsOther

Segment by ApplicationHospitalClinicMedical Research InstitutionOther

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2542097&licType=S&source=atm

The study objectives of Cancer Stem Cell Therapy Market Report are:

To analyze and research the Cancer Stem Cell Therapy market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Cancer Stem Cell Therapy manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Cancer Stem Cell Therapy market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the keyword market.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2542097&source=atm

See the original post:
Cancer Stem Cell Therapy Market Global Size, Demand-sales, Suppliers by Key Applications 2019 Detailed Analysis and Growth Aspects on Manufacturing...

Posted in Cell Therapy | Comments Off on Cancer Stem Cell Therapy Market Global Size, Demand-sales, Suppliers by Key Applications 2019 Detailed Analysis and Growth Aspects on Manufacturing…

Canine Stem Cell Therapy Market to Witness Growth Acceleration During 2029 – Monroe Scoop

Posted: March 15, 2020 at 2:46 pm

Canine Stem Cell Therapy Market size will reach xx million US$ by 2029, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and2029 as the forecast period to estimate the market size for Canine Stem Cell Therapy.

This industry study presents the Canine Stem Cell Therapy Market size, historical breakdown data 2014-2019 and forecast 2029. The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Canine Stem Cell Therapy Market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/2360

Canine Stem Cell Therapy Market report coverage:

The Canine Stem Cell Therapy Market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Canine Stem Cell Therapy Market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The study objectives are Canine Stem Cell TherapyMarket Report:

In this study, the years considered to estimate the market size of Canine Stem Cell TherapyMarket:

History Year: 2014 2018

Base Year: 2018

Estimated Year: 2019

Forecast Year:2029

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Canine Stem Cell Therapy Market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/2360

The report covers exhaustive analysis on:

Regional analysis includes

Get Full Report Access athttps://www.xploremr.com/cart/2360/SL

Benefits of Purchasing from XMR:

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id-[emailprotected]Web-https://www.xploremr.com

Read the rest here:
Canine Stem Cell Therapy Market to Witness Growth Acceleration During 2029 - Monroe Scoop

Posted in Cell Therapy | Comments Off on Canine Stem Cell Therapy Market to Witness Growth Acceleration During 2029 – Monroe Scoop

Stem cells can reverse damage caused by heart attack; repair mechanism discovered: Study – International Business Times, Singapore Edition

Posted: March 15, 2020 at 2:46 pm

Revolutionary Gene-Editing Tool

Cardiovascular or heart disease (CVDs) is the leading cause of death across the world. Heart attacks resulting due to CVDs can cause death, and severe damage to cardiac muscle a muscle that forms the wall of the heart in survivors. However, researchers claim that they have discovered stem-cell activated mechanisms that promote healing after a heart attack.

According to the study by researchers from Mayo Clinic, stem cells were found to reverse the damage and restore cardiac muscle back to its condition before a heart attack. Human cardiopoietic cells obtained from stem cells within the bone marrow were found to hone in on damaged proteins and reverse intricate changes that a heart attack caused.

"The response of the diseased heart to cardiopoietic stem cell treatment revealed development and growth of new blood vessels, along with new heart tissue," said Dr. Kent Arrell, first author of the study, in a statement.

For the study, the researchers examined the diseased hearts of mice. The hearts of mice that received human cardiopoietic stem cell therapy were compared with those of that did not. Nearly 4,000 cardiac proteins were identified using a data science technique to map proteins found in the cardiac muscle. Over 10 per cent of the discovered proteins were found to suffer damage as a result of a heart attack.

"While we anticipated that the stem cell treatment would produce a beneficial outcome, we were surprised how far it shifted the state of diseased hearts away from disease and back toward a healthy, pre-disease state," said Dr. Arrell.

While the organs in the human body have the ability to repair their damaged cells, they may be unable to restore the loss entirely, and this holds good for cardiac cells as well. Dr. Andre Terzic, senior author of the study, said: "The extent of change caused by a heart attack is too great for the heart to repair itself or to prevent further damage from occurring."

He explained that upon the administration of cardiopoietic stem cell therapy to mice, a partial or complete reversal of nearly two-thirds of the damage caused by a heart attack was noted. Around 85 per cent of all cellular functional categories struck by the disease responded favorably to the treatment.

According to the World Health Organisation (WHO), CVDs claim nearly 18 million lives every year, which translates to 31 per cent of all deaths. The findings of the study provide an improved understanding of the restoration of heart health using stem cells and provide a framework for wider utilization of stem cell therapy for the treatment of various conditions.

Stressing that the actual mechanism behind the repair of diseased organs by stem cells is poorly understood, Dr. Terzic added: "This study sheds light on the most intimate, yet comprehensive, regenerative mechanisms paving a road map for responsible and increasingly informed stem cell application."

See the original post here:
Stem cells can reverse damage caused by heart attack; repair mechanism discovered: Study - International Business Times, Singapore Edition

Posted in Cell Therapy | Comments Off on Stem cells can reverse damage caused by heart attack; repair mechanism discovered: Study – International Business Times, Singapore Edition

Page 1,111«..1020..1,1101,1111,1121,113..1,1201,130..»